Targeted strategies in the treatment of metastatic colon cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 9, 2007, Pages 983-990

  Reidy, Diane ^a   Saltz, Leonard ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Metastatic colon cancer; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OXALIPLATIN; PANITUMUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VATALANIB;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; HUMAN; METASTASIS; RASH; REVIEW; TUMOR GROWTH;

EID: 35948955912     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0082     Document Type: Review

References (41)

1. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14-20.
2. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
3. Punt CJ, Koopman, M, Douma J, et al. Sequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): a Dutch Colorectal Cancer Group (DCCG) phase III study [abstract]. J Clin Oncol 2007;25(Suppl 1):166s. Abstract 4012.
4. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.
5. Manegold J, von Pawel P, Zatloukal R, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract]. J Clin Oncol 2007;25(Suppl 1):388s. Abstract LBA7514.
6. Reidy D, Chung KY, Timoney JP, et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 2007;25:2691-2695.
7. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
9. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC) [abstract]. Presented at the ASCO 2007 Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, Florida. Abstract 238.
10. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer [abstract]. J Clin Oncol 2007;25 (Suppl 1):170s Abstract 4028.
11. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract]. J Clin Oncol 2005;23(Suppl 1):1s. Abstract 2.
12. Grothey A, Sugrue M, Hedrick E, et al. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE) [abstract]. J Clin Oncol 2007;25(Suppl 1):172s. Abstract 4036.
13. Saltz L, Rubin M, Hochster H. Cetuximab plus irinotecan is active in CPT-11 refractory colorectal cancet that expresses epidermal growth factor [abstract]. J Clin Oncol 2001;20(Suppl 1): Abstract 7.
14. Saltz LB, Meropol NJ, Loehrer PJ, et al. Single agent IMC-C225 (Erbitux) has activity in CPT-11 refractory colorectal cancer that expresses the epidermal growth factor receptor [abstract]. J Clin Oncol 2002;21(Suppl 1): Abstract 504.
15. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
16. Camp ER, Summy J, Bauer TW, et al. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 2005;11:397-405.
17. Jonker DJ, Karapetis CS, Moore M, et al. Randomized phase III trial of cetuximab monotherapy plus best supportive care versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (ACITC) [abstract]. Presented at the 2007 American Association of Cancer Research Annual Meeting; April 14-18,2007; Los Angeles, California. B-1a.
18. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial [abstract]. J Clin Oncol 2007;25(Suppl 1):164s. Abstract 4000.
19. Hecht JR, Patnaik A, Malik I, et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis [abstract]. J Clin Oncol 2004;22(Suppl 1): Abstract 3511.
20. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr) [abstract]. J Clin Oncol 2006;24(Suppl 1):158s. Abstract 3548.
21. Van Cutsem E, Peeters M, Siena S, et al. An open label phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) vs BSC alone in patients with metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
22. Amgen. Amgen discontinues Vectibix(TM) treatment in PACCE trial evaluating Vectibix(TM) as part of triple combination regimen. Press Release 3/22/2007. Available at http://www.amgen.com/media/media_pr_detail.jsp? releaseID=977186. Accessed August 28, 2007.
23. Engstron PF, Arnoletti JP, Benson AB III, et al. NCCN Colon Cancer guidelines, version 2, 2007. Available at http://www.nccn.org/professionals/ physician_gls/default.asp. Accessed August 28, 2007.
24. Saltz LB. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract]. J Clin Oncol 2003;22(Suppl 1): Abstract 817.
25. Saltz LB, Perez-Soler R. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23:5235-5246.
26. Saltz L, Easley C, Kirkpatrick P. Panitumumab. Nat Rev Drug Discov 2006;5:987-988.
27. Chung KY, Fusco A, Park R. Evaluation of routine antihistamine premedication after the first 2 doses of cetuximab [abstract]. Presented at the ASCO 2007 Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, Florida. Abstract 357.
28. Allen RM, Goldberg RM, Berlin J, et al. Unusually high rates of hypersensitivity to cetuximab in the middle-southern United States: association with atopic phenotype [abstract]. J Clin Oncol 2007;25(Suppl 1):505s. Abstract 9051.
29. Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006;12(7 Pt 1):2197-2207.
30. Saltz LB, Lenz HJ, Hochster H, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer: the "BOND-2" study. J Clin Oncol, in press.
31. Lenz HJ, Marshall J, Rosen L, et al. Phase II trial of SU11248 in patients with metastatic colorectal cancer (MCRC) after failure of standard chemotherapy [abstract]. Presented at the ASCO 2007 Gastrointestinal Cancers Symposium; January 26-28, 2007; San Francisco, California. Abstract 241.
32. Leong S, Eckhardt G, Chan E, et al. A phase I study of sunitinib in combination with modified FOLFOX 6 (mFOLFOX6) chemotherapy [abstract]. Presented at the ASCO 2007 Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, Florida. Abstract 285.
33. Starling N, Cunningham D, Vazquez F, et al. A phase I study of sunitinib in combination with FOLFIRI chemotherapy in treatment-naive, metastatic colorectal cancer [abstract]. Presented at the ASCO 2007 Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, Florida. Abstract 319.
34. Hecht R, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK222584 or placebo (CONFIRM1) [abstract]. J Clin Oncol 2005;23(Suppl 1): LBA3. Abstract 3.
35. Koehne C, Bajetta E, Lin E, et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK222584 (PRT/ZK) or placebo (CONFIRM2) [abstract]. J Clin Oncol 2006;24(Suppl 1):148s. Abstract 3508.
36. Rothenberg ML, Lafleur B, Levy DE, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005;23:9265-9274.
37. Keilholz U, Arnold D, Niederle N, et al. Etlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial [abstract]. J Clin Oncol 2005;23(Suppl 1):264s. Abstract 3575.
38. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR. Mol Cancer Res 2005;5:203-220.
39. Baselga J, Schoffski P, Rojo F, et al. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitot (TKI) gefitinib (G) in patients with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2006;24(Suppl 1):122s. Abstract 3006.
40. LeRoith D, Helman L. The new kid on the block (ade) of the IGF-1 receptor. Cancer Cell 2004;5:201-202.
41. Tabernero J, Rojo F, Burris H, et al. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors [abstract]. J Clin Oncol 2005;23 (Suppl 1):193s. Abstract 3007.